PREVNAR 13

Medicine identity

Source reference

82074

DIN

02335204

Form

Suspension

Company as listed by source

PFIZER CANADA ULC

Source status

Cancelled Post Market (2026-05-14)

Source last updated

2026-05-25

Source-listed ingredients

• PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1 — 2.2 MCG — per 0.5 ML
• PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3 — 2.2 MCG — per 0.5 ML
• PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 4 — 2.2 MCG — per 0.5 ML
• PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 5 — 2.2 MCG — per 0.5 ML
• PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6A — 2.2 MCG — per 0.5 ML
• PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6B — 4.4 MCG — per 0.5 ML
• PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F — 2.2 MCG — per 0.5 ML
• PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9V — 2.2 MCG — per 0.5 ML
• PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 14 — 2.2 MCG — per 0.5 ML
• PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 18C — 2.2 MCG — per 0.5 ML
• PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19A — 2.2 MCG — per 0.5 ML
• PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19F — 2.2 MCG — per 0.5 ML
• PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23F — 2.2 MCG — per 0.5 ML
• CORYNEBACTERIUM DIPHTHERIAE CRM-197 PROTEIN — 34 MCG — per 0.5 ML

These values do not establish equivalence or a dose recommendation.

Packages

• 1 Pre-Filled Syr/10 Pre-Fill Syr

Source and coverage

Open Health Canada Drug Product Database →

Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.

Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.